TScan Therapeutics, Inc. (TCRX)
Data as of , from SEC Form 4 filings.
See up to 3 months of TCRX. The 7-day demo opens the 1M and 3M ranges and puts TCRX on your watchlist.
Start 7-day demoLatest TCRX insider trades
About TScan Therapeutics, Inc. (TCRX)
TScan Therapeutics, Inc. files with the SEC under CIK 0001783328 and is classified as biological products (no diagnostic substances). We track it alongside the rest of the Health Care sector.
TCRX Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 2 | 1,300,000 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
TCRX insider transactions (Form 4)
2823 Form 4 filings on record, the earliest from Nov 19, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
 Gavin Macbeath - Officer | Grant or award | Voting Common Stock | 1,000,000 | $0.00 | - | |
 Zoran Zdraveski - Officer | Grant or award | Voting Common Stock | 300,000 | $0.00 | - | |
| BAKER BROS. ADVISORS LP | Grant or award | Non- Qualified Stock Option (right to buy) | 67,000 footnote F1 | $0.00 | - | |
| BAKER BROS. ADVISORS LP | Grant or award | Non- Qualified Stock Option (right to buy) | 67,000 footnote F1 | $0.00 | - | |
| ||||||
| Keith Woods | Grant or award | Stock Option (Right to Buy) | 67,000 | $0.00 | - | |
| Garry A. Nicholson | Grant or award | Stock Option (Right to Buy) | 67,000 | $0.00 | - | |
| Gabriela Gruia | Grant or award | Stock Option (Right to Buy) | 67,000 | $0.00 | - | |
| Katina Dorton | Grant or award | Stock Option (Right to Buy) | 67,000 | $0.00 | - | |
| Barbara Klencke | Grant or award | Stock Option (Right to Buy) | 67,000 | $0.00 | - | |
 Jason Amello - Officer | Grant or award | Stock Option (Right to Buy) | 350,000 | $0.00 | - | |
| Gavin Macbeath - Officer | Grant or award | Stock Option (Right to Buy) | 1,165,000 | $0.00 | - | |
| Leiden Dworak - Officer | Grant or award | Stock Option (Right to Buy) | 100,000 | $0.00 | - | |
| Chrystal Louis - Officer | Grant or award | Stock Option (Right to Buy) | 420,000 | $0.00 | - | |
| Zoran Zdraveski - Officer | Grant or award | Stock Option (Right to Buy) | 350,000 | $0.00 | - | |
| Lynx1 Capital Management LP - 10% Owner | Open-market purchase | Common stock, $0.0001 par value per share ("Common Stock") | 80,069 | $0.90 footnote F1 | $72K | |
| Lynx1 Capital Management LP - 10% Owner | Open-market purchase | Common Stock | 75,500 | $0.90 | $68K | |
| Lynx1 Capital Management LP - 10% Owner | Open-market purchase | Common Stock | 6,232 | $0.90 footnote F3 | $6K | |
| ||||||
| Gabriela Gruia | Grant or award | Stock Option (Right to Buy) | 67,000 | $0.00 | - | |
| Keith Woods | Grant or award | Stock Option (Right to Buy) | 67,000 | $0.00 | - | |
| Barbara Klencke | Grant or award | Stock Option (Right to Buy) | 67,000 | $0.00 | - | |
| Garry A. Nicholson | Grant or award | Stock Option (Right to Buy) | 67,000 | $0.00 | - | |
| Katina Dorton | Grant or award | Stock Option (Right to Buy) | 67,000 | $0.00 | - | |
| BAKER BROS. ADVISORS LP | Grant or award | Non- Qualified Stock Option (right to buy) | 67,000 | $0.00 | - | |
| BAKER BROS. ADVISORS LP | Grant or award | Non- Qualified Stock Option (right to buy) | 67,000 | $0.00 | - | |
| Lynx1 Capital Management LP - 10% Owner | Open-market purchase | Pre-funded Warrant (right to buy) | 7,500,000 | $4.00 | $30.00M | |
| Lynx1 Capital Management LP - 10% Owner | Open-market purchase | Common stock, $0.0001 par value per share ("Common Stock") | 31,800 | $3.01 | $96K | |
| Lynx1 Capital Management LP - 10% Owner | Open-market purchase | Common Stock | 100,000 | $2.90 | $290K | |
| Lynx1 Capital Management LP - 10% Owner | Open-market purchase | Common stock, $0.0001 par value per share | 947 | $4.34 | $4K | |
TCRX insider trading FAQ
What is the latest insider trade for TCRX?
TScan Therapeutics, Inc. (TCRX) had 2 insider filings in the last 90 days, with the most recent on 2026-10-02. The full record for TCRX runs to 23 Form 4 filings, the earliest from 2024-11-19. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying TCRX stock?
No insider purchases of TCRX were filed in the last 90 days. 7 purchases are on record for this company.
How many insiders are selling TCRX stock?
No insider sales of TCRX were filed in the last 90 days.
Where can I see TCRX SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects TCRX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Gavin Macbeath view on EDGAR
- - Zoran Zdraveski view on EDGAR
- - BAKER BROS. ADVISORS LP view on EDGAR
- - Keith Woods view on EDGAR
- - Garry A. Nicholson view on EDGAR
- - Gabriela Gruia view on EDGAR
- - Katina Dorton view on EDGAR
- - Barbara Klencke view on EDGAR
- - Jason Amello view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where TCRX's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow TCRX with a 7-day demo
- TCRX on your watchlist
- Every TCRX Form 4 filing on record
- Up to 3 months of TCRX price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
